North China Pharmaceutical Company.Ltd (SHA:600812)
China
· Delayed Price · Currency is CNY 5.27
+0.02 (0.38%)
Apr 29, 2026, 3:00 PM CST
SHA:600812 Revenue
North China Pharmaceutical Company.Ltd had revenue of 2.15B CNY in the quarter ending March 31, 2026, a decrease of -16.36%. This brings the company's revenue in the last twelve months to 8.82B, down -10.78% year-over-year. In the year 2025, North China Pharmaceutical Company.Ltd had annual revenue of 9.24B, down -6.36%.
Revenue (ttm)
8.82B
Revenue Growth
-10.78%
P/S Ratio
1.03
Revenue / Employee
874.36K
Employees
10,000
Market Cap
9.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.24B | -627.92M | -6.36% |
| Dec 31, 2024 | 9.87B | -250.63M | -2.48% |
| Dec 31, 2023 | 10.12B | -379.75M | -3.62% |
| Dec 31, 2022 | 10.50B | 115.37M | 1.11% |
| Dec 31, 2021 | 10.38B | -1.11B | -9.64% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Changzhou Qianhong Biopharma CO.,LTD | 1.48B |
| Harbin Pharmaceutical Group | 15.96B |
| PharmaBlock Sciences (Nanjing) | 2.03B |
| Shenzhen Neptunus Bioengineering | 27.28B |
| Zhejiang Xianju Pharmaceutical | 3.76B |
| Chongqing Taiji Industry(Group) Co.,Ltd | 10.50B |
| Hubei Hongyuan Pharmaceutical Technology | 1.77B |
| Beijing Foyou Pharma CO.,LTD | 3.49B |